Nodal positivity was identified in 22 patients (29.0%) with HR+/HER2− tumours, 12 patients (13.8%) with HR+/HER2+ tumours, 3 patients (5.6%) with HR−/HER2+ tumours, and 10 patients (6.5%) with TNBC. Here, HR is linked to neoplasm.